RA
PRTK

Royce & Associates’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Royce & Associates’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-294,800
Closed -$1.27M – 1191
2019
Q3 		$1.27M Buy
294,800
+57,100
+24% +$228K 0.01% 773
2019
Q2 		$948K Sell
237,700
-80,000
-25% -$380K 0.01% 842
2019
Q1 		$1.7M Hold
317,700
– – 0.01% 780
2018
Q4 		$1.63M Sell
317,700
-76,669
-19% -$582K 0.01% 784
2018
Q3 		$3.83M Sell
394,369
-18,500
-4% -$187K 0.03% 663
2018
Q2 		$4.21M Buy
412,869
+23,200
+6% +$263K 0.03% 638
2018
Q1 		$5.07M Buy
389,669
+29,400
+8% +$438K 0.04% 564
2017
Q4 		$6.45M Buy
360,269
+67,069
+23% +$1.4M 0.04% 514
2017
Q3 		$7.36M Buy
293,200
+10,300
+4% +$240K 0.05% 464
2017
Q2 		$6.82M Buy
282,900
+150,300
+113% +$3.32M 0.05% 497
2017
Q1 		$2.55M Buy
+132,600
New +$2.09M 0.02% 787

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 50.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates's PRTK Position: Q4 2019 in Review

Royce & Associates sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2019, closing a stake of 294,800 shares — an estimated $1.27M sold.

Royce & Associates first reported a position in PRTK in Q1 2017 and held it in 11 quarters. The position peaked at $7.36M in Q3 2017. 93 funds tracked by Wall St. Rank hold PRTK as of Q4 2019.

  • Royce & Associates reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Royce & Associates sold 294,800 Paratek Pharmaceuticals, Inc. shares in Q4 2019, an estimated $1.27M.
  • Royce & Associates first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 11 quarters.
  • Royce & Associates's Paratek Pharmaceuticals, Inc. position peaked at $7.36M in Q3 2017.
  • 93 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2019.

Based on Royce & Associates's 13F filing for Q4 2019, filed 6 Feb 2020.